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WITH SEVERE OA: RESULTS FROM A RANDOMIZED, DOUBLE-
BLIND, MULTICENTRIC CLINICAL TRIAL
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Purpose: To investigate soluble osteoarthritis (OA) biomarkers (Coll2-1,
Coll2-1NO2 and Fib3-2) in the per-protocol (PP) population of the
double-blind Multicentre Osteoarthritis interVEntion trial with Sysadoa
(MOVES) comparing the symptomatic efﬁcacy and safety of Chondroitin
Sulfate (CS) plus Glucosamine Hydrochloride (GH) versus CElecoxib
(CE) in patients with knee OA. Coll2-1 is a peptide located in the triple
helical part of type II collagen and Coll2-1NO2 is the nitrated form of
Coll2-1. Fib3-2 is a fragment of ﬁbulin-3, an extracellular glycoprotein
highly expressed in OA cartilage. The levels of these biomarkers have
been found to be elevated in serum of OA patients and to vary with
severity.
Methods: Coll2-1, mColl2-1NO2 and Fib3-2 were directly measured by
immunassays (ARTIALIS SA, Liege, Belgium) in the serum of the PP
population of the MOVES trial, which included 606 patients with knee
OA receiving 400 mg of CS plus 500 mg of GH three times daily or 200
mg of CE once daily for 6 months. This PP population included 418
subjects (215 receiving CSþGH and 203 receiving CE) with at least one
biomarker value at three time points (D0, D120 and D180).
Results: Serum biomarkers values at baseline or at follow-up D120 and
D180 were not associasted with age, sex, race, weight, height of BMI. In
overall PP population, there were no statistically signiﬁcant differences
between CE and CS þ GH groups for any of the three biomarkers at
baseline, D120 and D180. However, there was a trend in favor of CSþGH
in reducing Coll2-1 at D180 (p¼0.069) and a trend in favor of CE to
reduce Fib3-2 (p¼0.055). When population was stratiﬁed according the
radiological OA severity, the occurrence of a swelling or effusion event,
the WOMAC score or the sympromatic response to treatment some
signiﬁcant differences in biomarkers serum levels were observed
between treatment groups. At D180, CS þGH induced a signiﬁcantly
greater decrease of Coll2-1 in the subgroups of patients with the more
severe radiographic disease (K&L III), with synovitis (at least one joint
swelling or effusion event, in OMERACT-OARSI responders or in patients
with WOMAC pain at baseline  369 compared to CE (p<0.05). For
Coll2-1NO2, therewas a trend in favor of CSþ GH in the sub-population
having at least one joint swelling event during the study period
(p¼0.077) at D180. In addition, CE was more effective than CS þ GH in
reducing Fib3-2 at D180 in patients withWOMAC pain at baseline> 369
(p¼0.042).
Conclusions:CSþGHwasmoreefﬁcient thanCE in reducingserumColl2-
1, amarkerof type II collagendegradation. Thisdata indicates thatCSþGH
may down-regulate cartilage catabolism, particularly in a subgroup of
patients with severe OA. These results are in accordance with the symp-
tomatic beneﬁts observed in the clinical trials with these therapies.
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ASSOCIATIONS OF SERUM BIOMARKERS WITH RESPONSE TO SPINAL
PROCEDURES IN SUBJECTS WITH AXIAL LOW BACK PAIN
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M. Cortazzo, N. Vo, J. Kang, G. Sowa. Univ. of Pittsburgh, Pittsburgh, PA,
USAPurpose:Despite increasing numbers of interventional procedures being
performed for axial low back pain, selection criteria remain unclear and
outcomes suboptimal. Serum biomarkers represent a potential oppor-
tunity to improve clinical ability to predict response to treatment and
provide insight into mechanisms of action of procedures such as spinal
injections. The purpose of this study was to examine the association of
serumbiomarkerswithpainandpain relateddisability in individualswith
axial low back pain undergoing different spinal procedures.
Methods: Consecutive patients 18 years or older were recruited from
academic medical center departments of Physical Medicine and Reha-
bilitation and Anesthesiology who had already consented for either
epidural steroid injection (ESI, n¼48) or medial branch block without
steroid (MBB, n¼45) as part of their routine clinical care. Subjects were
eligible if they had primarily axial low back pain that was more severe
than pain in any other part of the body, and did not have radiation of
pain into the lower extremities, red ﬂags of serious underlying illness
(such as fever, weight change, bowel or bladder changes or neurologic
decline), recent oral steroids, uncontrolled psychiatric illness, or sys-
temic inﬂammatory conditions.
Serum blood samples were taken immediately prior to the procedure
and at clinical follow-up and assayed for Neuropeptide Y, E-selectin,
RANTES, CS846, CTXII, and serotonin. Responders to injection were
deﬁned as improvement in pain score of 2 points or more on a 0-10
numeric pain rating scale (immediately following the procedure for
MBB, and at follow-up for ESI). Gender, age, race, education, employ-
ment status, smoking status, Oswestry disability index, Roland Morris
Disability, McGill Pain Questionnaire, Generalized Anxiety, PHQ-9,
walking speed, fear avoidance beliefs, catastrophizing, cumulative ill-
ness rating scale, prior treatments and exercise, treatment expectation,
and medications were also collected. Wilcoxon rank sum and Fisher’s
exact tests were used for comparing responders and non-responders.
Results: Response rates were 78% and 48% for MBB and ESI, respec-
tively. Among subjects undergoing MBB, responders had higher base-
line RANTES levels than non-responders (p¼0.04). Among subjects
undergoing ESI, responders had lower baseline CS846 levels (p¼0.04),
greater frequency of past exercise (p¼0.04), and greater percentage
expecting relief (p¼0.04) than non-responders. No other associations
were observed with other baseline clinical variables.
Among subjects undergoing MBB, serotonin concentrations increased
pre- to post-procedure in non-responders and decreased in responders
(responder to non-responder difference p¼0.048). Among subjects
undergoing ESI, E-selectin showed a tendency toward more decreased
levels post-procedures in responders (p¼0.1).
Conclusions: These data identify candidate serum biomarkers that may
have utility for patient selection for spinal procedures. Because clinical
decision making for interventional management for axial low back pain
is even more challenging than for radiculopathy, these represent
important biomarkers for use in prospective studies to assess and val-
idate their predictive ability. In addition, the associated biomarkers may
provide useful insight into the mechanism of spinal procedures by
identifying important targets for future study. Larger studies are needed
to conﬁrm the utility of these identiﬁed biomarker candidates.
109
IDENTIFICATION AND CLINICAL CHARACTERIZATION OF
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Purpose: A proportion the osteoarthritis (OA) patients experience joint
inﬂammation with associated pain and discomfort. However to present
day, there are limited objective measures available for monitoring and
identify those patients who have inﬂammatory OA. The aim of this
study was study the association between joint inﬂammation and bio-
markers associated with connective tissue inﬂammation and cartilage
degradation.We used four biomarkers that have previously been shown
to be associated with inﬂammation and joint destruction.
Methods: Biomarkers were measured in 288 women and 186 menwith
OA and mean age of 64.2 year (SD 7.6) from the VIDEO cohort. Knee
effusion, clinical signal of synovitis and WOMAC pain, stiffness and
function, and ESR were recorded for each patient. Serum levels of the
connective tissue biomarkers C3M and CRPM (type III collagen and C-
reactive protein neo-epitopes, Nordic Bioscience), urinary CTX-II/crea-
tinin [IDS PLC] (type II collagen neo-epitopes) and serum COMP
